BioCentury
ARTICLE | Company News

University of Texas MD Anderson Cancer Center, Angle deal

February 23, 2015 8:00 AM UTC

Angle and MD Anderson will use Angle’s Parsortix system to determine which colorectal cancer patients will benefit from treatment with Erbitux cetuximab. The center will recruit 50 metastatic colorec...